Shares of clinical-stage biotech Editas Medicine (NASDAQ: EDIT) rose as much as 14% on Monday, lifted by a trend over the past couple of days favoring gene-editing stocks. Editas stock also benefited ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results